Literature DB >> 16236492

Measuring the effects of COPD on the patient.

Paul Jones1, Suzanne Lareau, Donald A Mahler.   

Abstract

Evaluation of the effectiveness of treatment for chronic obstructive pulmonary disease (COPD) requires the assessment of both clinical and physiological measures. Parameters such as the forced expiratory volume in 1 s are well established in providing an indication of the degree of airflow limitation. However, additional measurements, such as dyspnoea, functional status and health status, are required to provide a complete picture of COPD. Indeed, dyspnoea is the predominant symptom of COPD experienced by the patient, which treatment is designed to reduce. Methods of assessing dyspnoea have developed over the previous five decades. The most widely used instruments for assessing the impact of dyspnoea are the baseline dyspnoea index, the transition dyspnoea index and the Medical Research Council Questionnaire. A more comprehensive approach to the assessment of disability caused by dyspnoea and fatigue is provided by assessments of functional status, such as the pulmonary functional status and dyspnoea questionnaire. Respiratory-specific health status questionnaires, such as the St. George's Respiratory Questionnaire, attempt to capture the wide range of effects of COPD into a single score that reflects the overall impact of the disease. Developing the means to measure the effects of COPD is important, both in terms of understanding disease pathophysiology for research purposes, and in terms of accurately assessing the effects of treatment on the patient. Future developments will include computerising these methodologies to permit faster and more individual patient-centred measurements.

Entities:  

Mesh:

Year:  2005        PMID: 16236492     DOI: 10.1016/j.rmed.2005.09.011

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  19 in total

Review 1.  Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease.

Authors:  Kunal Srivastava; Deepika Thakur; Sheetal Sharma; Yogesh Suresh Punekar
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

2.  Socioeconomic Characteristics Are Major Contributors to Ethnic Differences in Health Status in Obstructive Lung Disease: An Analysis of the National Health and Nutrition Examination Survey 2007-2010.

Authors:  Carlos H Martinez; David M Mannino; Jeffrey L Curtis; MeiLan K Han; Alejandro A Diaz
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

3.  Development and validation of the living with chronic obstructive pulmonary disease questionnaire.

Authors:  Stephen P McKenna; David M Meads; Lynda C Doward; James Twiss; Robin Pokrzywinski; Dennis Revicki; Cameron J Hunter; G Alastair Glendenning
Journal:  Qual Life Res       Date:  2011-02-11       Impact factor: 4.147

4.  Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium.

Authors:  Kai-Michael Beeh; Jutta Beier; James F Donohue
Journal:  Respir Res       Date:  2012-06-22

5.  Clinical management practices adopted by physiotherapists in India for chronic obstructive pulmonary disease: A national survey.

Authors:  Aripta Jingar; Gopala Krishna Alaparthi; K Vaishali; Shyam Krishnan; B Unnikrishnan
Journal:  Lung India       Date:  2013-04

6.  Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.

Authors:  Didier Renard; Michael Looby; Benjamin Kramer; David Lawrence; David Morris; Donald R Stanski
Journal:  Respir Res       Date:  2011-04-26

7.  COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population.

Authors:  Monica J Fletcher; Jane Upton; Judith Taylor-Fishwick; Sonia A Buist; Christine Jenkins; John Hutton; Neil Barnes; Thys Van Der Molen; John W Walsh; Paul Jones; Samantha Walker
Journal:  BMC Public Health       Date:  2011-08-01       Impact factor: 3.295

8.  Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.

Authors:  Edward Kerwin; Jacques Hébert; Nicola Gallagher; Carmen Martin; Tim Overend; Vijay K T Alagappan; Yimeng Lu; Donald Banerji
Journal:  Eur Respir J       Date:  2012-07-26       Impact factor: 16.671

Review 9.  Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.

Authors:  Roland Buhl; Donald Banerji
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-10-26

Review 10.  Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials.

Authors:  Jiangna Han; Lu Dai; Nanshan Zhong
Journal:  BMC Pulm Med       Date:  2013-04-25       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.